3 ms·
Low GLP1 Therapy Maintains Weight, Body Composition, & Metabolic Improvements
- randycupertino 8mo agoA study of users of semaglutide and tirzepatide found that every other week dosing at their current dose led to weight loss maintenance (and slight weight loss) over 36 weeks. Methods: This retrospective case series included 30 adults who achieved weight plateau while on weekly semaglutide or tirzepatide. Patients transitioned to reduced-frequency dosing (usually every other week) at their existing dose. Results: Patients maintained reduced-frequency dosing for an average of 36.3 weeks. Weight decreased from 87.9 ± 2.4 kg at pre-treatment to 74.1 ± 2.4 kg at plateau and further to 72.4 ± 2.2 kg on maintenance dosing (p < 0.01). Total body and truncal fat declined, while skeletal muscle mass stabilized on the reduced-frequency regimen. Metabolic parameters improved during weekly dosing and these gains were maintained during reduced-frequency therapy. Conclusions: In patients with prior weight loss and metabolic improvement on GLP1 therapy, reduced-frequency maintenance dosing preserved outcomes.
- toomuchtodo 8mo agoThis will pair nicely with recently deployed oral protocols.
- jamesgill 8mo agoI have no objections to the drug, but it’s also been well-established and well documented that you can achieve all these effects and results with a ketogenic (or similar) diet.
- hezeclark 7mo agoconnect to